Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing three active ingredients: morphine, oxycodone, and acetaminophen. Morphine and oxycodone are both opioid analgesics that act primarily as agonists at the mu-opioid receptor in the central nervous system, leading to inhibition of pain signaling and providing potent analgesia. Acetaminophen is a non-opioid analgesic and antipyretic that works by inhibiting prostaglandin synthesis in the central nervous system, though its precise mechanism for pain relief remains not fully understood. This combination would be expected to provide strong pain relief for severe acute or chronic pain unresponsive to other treatments. However, there is no evidence from available sources that such a triple combination (morphine + oxycodone + acetaminophen) exists as an approved or marketed pharmaceutical product; combinations of two of these agents (e.g., oxycodone + acetaminophen) are widely used[1][3][6]. The use of multiple opioids together with acetaminophen would raise significant safety concerns regarding additive opioid toxicity (respiratory depression, sedation), risk of dependence/abuse, and potential for liver toxicity from high doses of acetaminophen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morphine + oxycodone + acetaminophen.